{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n CT47A8 is a member of the cancer/testis antigen family, a group of genes that are normally expressed only in germ cells but become aberrantly activated in several types of cancer. In breast cancer, for example, these antigens are frequently upregulated in estrogen receptor–negative ductal carcinoma in situ, where their expression is associated with HER2 positivity and an accompanying robust stromal immune response, suggesting that CT47A8 may contribute to tumor immunogenicity and serve as an attractive target for immunotherapeutic strategies (1). In prostate cancer, similar cancer/testis antigens have been explored as diagnostic as well as prognostic biomarkers due to their ability to elicit specific autoantibody responses, emphasizing the potential of markers like CT47A8 in monitoring disease progression and treatment response (2). Although large‐scale transcriptome projects such as the CHESS database have broadened our catalog of human genes and revealed extensive transcriptional diversity, they provide an important context for understanding the expression profile of cancer/testis antigens in normal versus malignant tissues (3). Moreover, integrative genomic profiling studies in breast cancer survivors underscore the value of such genes as biomarkers that could help personalize treatment regimens and predict long‐term patient survivability, further highlighting the clinical relevance of CT antigens including CT47A8 (4).\n "}, {"type": "rg", "children": []}]}]}